Compare Iron Mountain Inc (IRM) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iron Mountain Inc vs Neurocrine Biosciences Inc — how do they compare? Iron Mountain Inc trades at $113.5 (market cap $34.46B), while Neurocrine Biosciences Inc trades at $141.09 (market cap $14.36B). The key difference: Iron Mountain Inc is far larger — about 2.4× Neurocrine Biosciences Inc's market cap, and Iron Mountain Inc pays a 2.99% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Iron Mountain Inc for 80 Days and Neurocrine Biosciences Inc for 23 Days on average.
| IRM | NBIX | |
|---|---|---|
Market Cap | $34.46B | $14.36B |
Volume | 1,379,608 | 1,237,180 |
Sector | Real Estate | Health |
52-Week High | $133.06 | $185.50 |
52-Week Low | $78.86 | $123.10 |
Typical Hold Time | 80 Days | 23 Days |
Enterprise Value | $53.87B | $14.37B |
Dividend Yield | 2.99% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Iron Mountain (IRM) trades at $115.73, down 0.66% on the day, with a bullish technical signal and strong analyst consensus. The company reported revenue growth to $6.90B in 2025, though net income margin compressed to 2.09%. Recent news highlights expansion in data centers and digital partnerships, while institutional investors like Bank of America and California State Teachers Retirement System increased holdings significantly in Q2 2026.
The outlook remains positive with a consensus price target of $142.75 implying 23% upside, supported by data center pipeline growth and digital cross-selling. Key risks include high debt levels with a debt-to-asset ratio of 79.04% in 2025 and margin pressure from rising interest expenses. Earnings beats in recent quarters reinforce execution strength, but valuation multiples like a P/E of 82.09 demand sustained growth.
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, with a bearish technical signal but strong fundamentals including a 20.91% net income margin and consistent earnings beats. Recent news highlights pipeline advancements in Prader-Willi syndrome and executive appointments, while analyst consensus remains strongly bullish with a $204.18 price target.
The outlook is positive based on robust profitability and growth initiatives, though risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharma company with a deep pipeline, balanced by near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Iron Mountain Inc
Iron Mountain Inc is a record management services provider. The firm is organized as a REIT. Most of its revenue comes from its storage business, with the rest coming from value-added services. The firm primarily caters to enterprise clients in developed markets. Its business segments include Global RIM Business
Read more on IRM →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
